-
Drug Marketing in China and Worldwide (August)(2023)
PharmaSources
September 01, 2023
The official website shows that the drugs developed by major companies have been declared for marketing.
-
PD-1 Inhibitor Combined with ADC, the Strong Cooperation of Innovent and Remegen
Far-away from the Crowd/PharmaSources
July 25, 2023
Recently, Innovent and Remegen will carry out a clinical research cooperation on the combination of Sintilimab Injection, a PD-1 inhibitor, with RC88, a novel antibody-drug conjugate targeting MSLN, and RC108, a novel ADC targeting c-MET, res.
-
Summary of Immune Checkpoint Inhibitor Combined with ADC
Yefenghong/PharmaSources
July 25, 2023
With the maturity of ADC technology, the combined scheme of IO and ADC is showing a therapeutic potential.
-
China API Market Overview
ChatGPT
July 20, 2023
The Active Pharmaceutical Ingredient (API) market in China has seen significant growth and development in recent years.
-
Pharmaceutical Business in China and Worldwide (June)
Caicai/PharmaSources
July 12, 2023
Pharmaceutical Business in China and Worldwide (June)
-
Drug Marketing in China and Worldwide (June)
Caicai/PharmaSources
July 12, 2023
Drug Marketing in China and Worldwide (June)
-
Pharmaceutical Business in China and Worldwide (May)
Caicai/PharmaSources
July 12, 2023
Pharmaceutical Business in China and Worldwide (May)
-
NMPA's Progress in Joining PIC/S
zhulikou431/PharmaSources
July 12, 2023
This article will introduce China NMPA's progress in joining PIC/S and the latest change in GMP guideline of PIC/S respectively.
-
Drug Marketing in China and Worldwide (May)
Caicai/PharmaSources
July 12, 2023
Drug Marketing in China and Worldwide (May)
-
CPHI & PMEC China 2023 Shines Bright!
PharmaSources
July 12, 2023
Forge Partnerships, Create Brilliance, The Real Inspiration of The New Chapter